🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK573719 62.5 mcg (one strip)

Found 15 matching trials

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study is a 12-week, multicenter, randomized, double blind, parallel gr...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-01

Trial ID

NCT02152605

Treatments Being Tested

UMEC/VI Placebo

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, placebo-controlled, 2-peri...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-23

Trial ID

NCT02275052

Treatments Being Tested

UMEC/VI DPI Placebo DPI Albuterol/salbutamol MDI

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

PHASE4

The primary objective of this study is to assess the effect of umeclidinium...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-14

Trial ID

NCT02799784

Treatments Being Tested

UMEC/VI TIO/OLO Albuterol/salbutamol

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

PHASE1

GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonis...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-10-12

Trial ID

NCT01521390

Treatments Being Tested

GSK573719 62.5 mcg (one strip)GSK573719 62.5 mcg(two strips)GSK573719 125 mcg (one strip)GSK573719 125 mcg(two strips)Placebo

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

PHASE2

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-01-25

Trial ID

NCT03012061

Treatments Being Tested

Placebo UMEC Fluticasone Furoate Albuterol/salbutamol

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a multicenter, randomized, double-blind, double-dummy, parallel gro...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-04-04

Trial ID

NCT01822899

Treatments Being Tested

Umeclidinium bromide/Vilanterol Placebo ACCUHALER/DISKUS Fluticasone propionate/Salmeterol Placebo NDPI

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

COPD is characterized by an airflow limitation, which is not fully reversib...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-16

Trial ID

NCT03034915

Treatments Being Tested

UMEC/VI 62.5/25 mcg via ELLIPTA UMEC 62.5 mcg via ELLIPTA Salmeterol 50 mcg via DISKUS Placebo via ELLIPTA Placebo via DISKUS

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The primary purpose of this study is to assess the equivalence of closed tr...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2016-06

Trial ID

NCT02731846

Treatments Being Tested

Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg Fluticasone furoate 100 mcg + Vilanterol 25 mcg Umeclidinium 62.5 mcg Placebo ELLIPTA inhaler Albuterol/Salbutamol

A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, parallel-group study to ev...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-30

Trial ID

NCT02257372

Treatments Being Tested

UMEC DPI Placebo DPI ICS/LABA medication Albuterol/salbutamol Metered Dose Inhaler (MDI)

Previous Next